FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions

The U.S. Food and Drug Administration has allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions.

Be the first to comment

Leave a Reply

Your email address will not be published.